Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q1 2025 Earnings Presentation
19 slides from Quanterix's earnings presentation, May 12, 2025
Slide 1: First Quarter 2025 Earnings
„ First Quarter 2025 Earnings May 12, 2025
Slide 2: Legal Information
Legal Information IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya”) by Quanterix (the “Merger”), Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a post-effective amendment to its registration statement o
Slide 3: Legal Information: Forward-Looking Statements
Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this presentation which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provi
Slide 4: Q1-25: Key Messages
Q1-25: Key Messages Record consumables performance with solid momentum for new assays Exceeded revenue expectations in first quarter Adjusted cash burn reduced by half $9.0M of adjusted cash burn in Q1-25 compared to $19.4M in previous year Early-access program, Simoa® ONE assay kits will become com
Slide 5: Well-positioned to deliver solutions meeting increasing demand in human health
Early detection Accelerate new therapies Precise monitoring Well-positioned Real-time insight to deliver Complement genetic data solutions meeting increasing Expand into Immunology and Oncology demand in human Lead through early biomarker detection health Create high sensitivity diag
Slide 6: Strategic Priorities
Grow Menu Extend #1 position in Neuro Strategic Expand Priorities into Adjacencies Immunology and Oncology Building on Top of our Base Translate into Diagnostics Clinical applications and Alzheimer’s Disease testing 6
Slide 7: Continued progress in growing menu portfolio
Continued progress in growing menu portfolio Menu Announced new dried- blood spot extraction (DBS) kit Launched Launched part of Quanterix’s industry- 20 new assays leading Simoa® assay kits 4 new assays One Multi-marker Growing consumables to Expect to launch 15 new assays in 2025 highest consumabl
Slide 8: Platform launch of Simoa ONE
Adjacencies Platform launch of Simoa ONE Simoa ONE instrument with kits Breaking past detection 10x more sensitive limits set by Simoa Up to 10-plex capability Enhanced specificity with Emission beads N E W P L AT F O R M L A U N C H END OF 2025 Simple, efficient workflow (3 hr. result) 8
Slide 9: Simoa ONE Assay Kits
Simoa in every lab: Access to ultra-sensitive biomarker detection Adjacencies Compatible with over 20,000 existing flow cytometers Simoa ONE worldwide Assay Kits Breakthrough in reagent Reduce customer need design: Simoa’s digital, for capital purchase Early access ultra-sensitive detection Expa
Slide 10: Akoya and Quanterix: Compelling combination to Expand into Oncology
Akoya and Quanterix: Compelling combination to Expand into Oncology Adjacencies Tissue leaks Biomarkers originating in biomarkers into blood SIMOA ultra-sensitivity tissue identified by Akoya’s detecting those spatial organization tools in ultra-low quantities markers in blood PDL-1 ORF1p IFN-γ sPD-
Slide 11: Customers Are Excited About the Combination
Customers Are Excited About the Combination Adjacencies We at Dana Farber/Brigham and Women’s Cancer Center and MGB are very excited about the prospect of combining information from blood plasma and from tissue to provide comprehensive, Jon Christopher Aster, MD, PhD longitudinal profiling of cancer
Slide 12: Building a global infrastructure for Alzheimer's Disease Testing
Building a global infrastructure for Alzheimer’s Disease Testing AD Dx PAR T 1 : E N AB L E M E N T PAR T 2 : O U R L AB 3 new diagnostics collaborations in the quarter including: PLA Codes approved a leading national for LucentAD & LucentAD reference laboratory in the Complete United States DEM O N
Slide 13: Preliminary Q1 2025 Results vs PYQ1
Preliminary Q1 2025 Results vs PYQ1 (In millions) Q1 GAAP Q1 Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2024 2025 2024 2025 Var % Revenue Mix 9% 60% 18% 13% Revenue 32.1 30.3 32.1 30.3 -5% Gross Margin $ 18.5 16.4 16.4 15.1 -8% Gross Margin % 57.8% 54.1% 51.2% 49.7% -150 Revenue Q1 2024 Q1 2
Slide 14: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Infectious Diseases Immunology & Oncology Others INSTRUMENTS PUBLICATIONS BIOMARKERS Placements Cumulative Cumulative # of units placed In millions USD Cumulative 38.0 264 Number of Drug 256 3,445 568 575 1,052 Trial Projects 559 1,035 538 972 3,278 2
Slide 15: 2025 Guidance – Standalone Quanterix
2025 Guidance – Standalone Quanterix Full Year Revenue: $120 to $130 million Excludes revenue from Lucent Diagnostics testing. Gross Margin GAAP Gross Margin between 55% to 59% and Adjusted Gross Margin (Non-GAAP) between 50% to 54%. $35 to $45 million of adjusted cash burn $20 million payment for E
Slide 16: Robust Balance Sheet
Robust Balance Sheet Cash1 $155M cash1 at close (Q2’25) 2026 >$100M Cash flow positive in 2026 >$100 million cash1 on hand by the 2025 ~$120M time we turn cash flow positive 1. Includes Cash, Cash Equivalents, Marketable Securities, and Restricted Cash balances from the Consolidated Balance Sheet. 1
Slide 17: Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) QUANTERIX CORPORATION RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES Reconciliation of Net Loss to Adjusted EBITDA (non-GAAP) and Adjusted EBITDA Margin (non-GAAP) (Unaudited, amounts in thousands except percentages) Three Months Ended March 31, 2025 2024 Net loss
Slide 18: Adjusted Cash Burn (non-GAAP)
Adjusted Cash Burn (non-GAAP)
Slide 19: Additional Non-GAAP Financial Measures
Additional Non-GAAP Financial Measures 19